A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Hoffmann-La Roche
Nuvectis Pharma, Inc.
Dutch Society of Physicians for Pulmonology and Tuberculosis
AstraZeneca
Eli Lilly and Company
AstraZeneca
Maia Biotechnology
Plexium, Inc.
Maia Biotechnology
EMD Serono
Delfi Diagnostics Inc.
Mayo Clinic
TScan Therapeutics, Inc.
Rondo Therapeutics
Bristol-Myers Squibb
Immuneering Corporation
Paradigm Health
Novartis
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
Immuneering Corporation
University of Birmingham
Creative Biosciences (Guangzhou) Co., Ltd.